

Title (en)

METHODS FOR SCREENING INHIBITORS AGAINST CHIKUNGUNYA VIRUS AND FOR DETERMINING WHETHER SUBJECTS ARE PREDISPOSED TO INFECTION BY SAID VIRUS

Title (de)

VERFAHREN ZUM SCREENING VON INHIBITOREN GEGEN DAS CHIKUNGUNYA-VIRUS UND ZUM BESTIMMEN, OB PROBANDEN FÜR EINE INFEKTION MIT DIESEM VIRUS PRÄDISPONIERT SIND

Title (fr)

PROCÉDÉS POUR CRIBLER DES INHIBITEURS CONTRE LE VIRUS CHIKUNGUNYA ET POUR DÉTERMINER SI DES SUJETS SONT PRÉDISPOSÉS À UNE INFECTION PAR LEDIT VIRUS

Publication

**EP 3908680 A1 20211117 (EN)**

Application

**EP 20700162 A 20200110**

Priority

- EP 19305036 A 20190111
- EP 19305978 A 20190724
- EP 2020050541 W 20200110

Abstract (en)

[origin: WO2020144324A1] Chikungunya virus (CHIKV) has caused recent outbreaks associated with severe morbidity. Currently no vaccine or treatment exists to protect humans from CHIKV infection. Treatment is therefore purely symptomatic and is based on non-steroidal anti-inflammatory drugs. Accordingly, there is a high medical need exists to have new methods of screening of compounds which could inhibit chikungunya virus. Further to a CRISPR-Cas9 genetic screen the inventors now identify the four and a half LIM domains protein 1 (FHL1) has an essential host factor for CHIKV infection. In particular, they show that primary myoblast and fibroblast from FHL1 deficient patient are resistant to CHIKV infection. They also demonstrate that depletion of FHL1 prevents CHIKV replication. Finally, they show that CHIKV non-structural protein 3 interacts specifically with FHL1A through its hypervariable domain. Thus compounds that are capable of inhibiting the interaction between the non-structural protein 3 and FHL1 would be suitable for inhibiting the replication capacity of the virus. Determining the expression level of FHL1 and/or identifying some genetic variant would also be suitable for determining whether some subjects are predisposed to CHIKV infection.

IPC 8 full level

**C12Q 1/70** (2006.01); **A61P 31/14** (2006.01); **C12N 15/10** (2006.01); **G01N 33/569** (2006.01)

CPC (source: EP US)

**A61P 31/14** (2017.12 - EP); **C12N 7/00** (2013.01 - US); **C12N 15/1055** (2013.01 - EP US); **C12Q 1/70** (2013.01 - EP); **C12Q 1/701** (2013.01 - US); **G01N 33/56983** (2013.01 - EP); **C12Q 2600/136** (2013.01 - EP); **Y02A 50/30** (2017.12 - EP)

Citation (search report)

See references of WO 2020144324A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

**WO 2020144324 A1 20200716**; EP 3908680 A1 20211117; EP 3908680 B1 20230301; ES 2942917 T3 20230607; US 2022098681 A1 20220331

DOCDB simple family (application)

**EP 2020050541 W 20200110**; EP 20700162 A 20200110; ES 20700162 T 20200110; US 202017421999 A 20200110